News

Kenox Pharmaceuticals Expands GMP Capabilities to Accelerate Development of OINDPs

Back

Princeton, NJ - Kenox Pharmaceuticals Inc (Kenox), is excited to announce the expansion of our GMP capabilities, a move that will significantly enhance our ability to support the development of orally inhaled and nasal drug products (OINDPs). This expansion reflects our commitment to driving innovation and maintaining the highest manufacturing standards for critical drug products. With these enhanced capabilities, Kenox is well-positioned to offer faster, more efficient development services for OINDPs, supporting the success of our clients’ projects.

For more information, see our recent news Click here.

If you would like to discuss your project or learn more about our capabilities, please reach out to us at bd@kenoxpharma.us.